CN
CN
BN104 Granted Orphan Drug Designation by US FDA for the Treatment of Acute Myeloid Leukemia
April 20, 2023

SHANGHAI, China, April. 20, 2023 - BioNova Pharmaceuticals Limited (BioNova), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to BN104 for the treatment of acute myeloid leukemia (AML).